MetaVia Inc. (NASDAQ:MTVA – Free Report) – HC Wainwright issued their Q4 2024 earnings estimates for shares of MetaVia in a report released on Monday, December 30th. HC Wainwright analyst E. Arce expects that the company will post earnings of ($0.74) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for MetaVia’s current full-year earnings is ($3.91) per share. HC Wainwright also issued estimates for MetaVia’s FY2025 earnings at ($2.61) EPS and FY2026 earnings at ($2.73) EPS.
MetaVia Trading Up 2.5 %
Shares of MTVA stock opened at $2.03 on Wednesday. MetaVia has a 12-month low of $1.51 and a 12-month high of $6.75.
MetaVia Company Profile
MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.
Read More
- Five stocks we like better than MetaVia
- Canada Bond Market Holiday: How to Invest and Trade
- 3 Stocks Helping to Bring AI to Healthcare
- 3 Small Caps With Big Return Potential
- 3 Stocks Ringing in The New Year With Large Buyback Announcements
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Why 2024 Was Great for Stocks—and Why 2025 Could Be Even Better
Receive News & Ratings for MetaVia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetaVia and related companies with MarketBeat.com's FREE daily email newsletter.
